40: Best abstract: Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe Ulcerative Colitis: Results from two phase 3 randomised controlled trialsECCO'16 Amsterdam
2016
1
41: Best abstract: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s Disease: Interim analysis from the phase 2 FITZROY studyECCO'16 Amsterdam
2016
1
46: Best abstract: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn’s Disease: Results of a Phase 2b randomised placebo-controlled trialECCO'16 Amsterdam
2016
1
47: Best abstract: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate to severe Crohn’s Disease: Results of a Phase 2b randomised placebo-controlled trialECCO'16 Amsterdam
2016
1
4: Abstract 2: Revised roles of matrix metalloproteinase/MMP-9 in Inflammatory Bowel Diseases/IBD: From target to biomarker2nd Y-ECCO Basic Science Workshop
2016
1
4: Best abstract: A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulae in Crohn’s DiseaseECCO'16 Amsterdam
2016
1
4: Session 3: What challenges are faced by using cross-sectional imaging and histological endpoints in clinical trials2nd Advanced ECCO: EduCational COurse for Industry
2016
1
4: What does the gastroenterologist want to know from the pathologist?1st H-ECCO IBD Masterclass
2016
1